Research Topics
Species | Scott KopetzSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Src continues aging: current and future clinical directionsScott Kopetz
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Clin Cancer Res 13:7232-6. 2007....
The promise of patient-derived xenografts: the best laid plans of mice and menScott Kopetz
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clin Cancer Res 18:5160-2. 2012..The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use...- Adjuvant chemotherapy for stage II colon cancerScott Kopetz
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncology (Williston Park) 22:260-70; discussion 270, 273, 275. 2008..The only phase III clinical trial for stage II patients currently ongoing in the United States uses molecular classification as the basis for patient randomization... - Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathwayScott Kopetz
Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
J Clin Oncol 26:2000-5. 2008..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer... 
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapyScott Kopetz
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 27:3677-83. 2009....- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz
University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
J Clin Oncol 28:453-9. 2010.... - Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastasesDipen M Maru
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Am J Surg Pathol 34:1287-94. 2010.... - Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastasesAndreas Andreou
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Ann Surg 256:642-50. 2012..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)... - Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?Antoine Brouquet
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer 117:4484-92. 2011..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown... - Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Invest New Drugs 26:445-54. 2008..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules... - Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer
Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 26:5344-51. 2008..The secondary goal of the study was to identify the clinical predictors of pathologic response... - Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastasesYun Shin Chun
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
JAMA 302:2338-44. 2009.... - Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?Antoine Brouquet
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
J Am Coll Surg 210:934-41. 2010..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined... - A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare diseaseMichael J Overman
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Ann Surg Oncol 19:1439-45. 2012..Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known... - Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastasesSusan B Kesmodel
Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 26:5254-60. 2008..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases... - Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestineMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Acta Oncol 49:474-9. 2010..We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma... - Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastasesYoji Kishi
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Ann Surg Oncol 17:2870-6. 2010..We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM... - High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcomeAntoine Brouquet
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
J Clin Oncol 29:1083-90. 2011..The impact of complete resection in this well-selected group is controversial... - Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injuryMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 28:2549-55. 2010..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia... - Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of VaterMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
J Clin Oncol 27:2598-603. 2009..We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin... - Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 casesMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
Clin Colorectal Cancer 7:338-42. 2008..Such trimodality therapy can result in durable palliation of symptoms and long-term survival for patients with recurrent CRC involving the duodenum and pancreas, even when other metastases are present... - Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapyYoji Kishi
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Ann Surg Oncol 16:614-22. 2009..Whether neutrophil-to-lymphocyte ratio (NLR) predicts survival of patients with colorectal liver metastases (CLM) treated with systemic chemotherapy remains unclear... - Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinomaMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:2038-45. 2008..The objective of this retrospective study was to determine whether the addition of a platinum compound to 5-FU provided any benefit in the treatment of patients with metastatic SBA... - Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastasesJunichi Shindoh
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 30:4566-72. 2012.... - Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injuryJulian H Slade
Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Clin Colorectal Cancer 8:225-30. 2009..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed... - Perioperative chemotherapy for resectable hepatic metastasesScott Kopetz
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Lancet 371:963-5. 2008 - Second-line chemotherapy use in metastatic colon cancer varies by disease responsivenessSeth Politano
University of Texas Health Science Center, Houston, TX, USA
Clin Colorectal Cancer 7:55-9. 2008..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen... - Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsMichael J Overman
University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
Cancer Invest 26:794-9. 2008..No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population... - CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumabPiyaporn Boonsirikamchai
Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
AJR Am J Roentgenol 197:W1060-6. 2011..The combined use of RECIST and morphologic criteria is mandatory for optimal evaluation in this population... - Long-term survival and recurrence outcomes following surgery for distal rectal cancerEric J Silberfein
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Ann Surg Oncol 17:2863-9. 2010..The purpose of this study is to evaluate operative and pathologic factors associated with long-term survival and local recurrence outcomes in patients treated for distal rectal cancer... - Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survivalYun Shin Chun
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
J Gastrointest Surg 11:1498-504; discussion 1504-5. 2007..The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy... - ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinomaMichael P Kim
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 6:e20636. 2011..Understanding which pancreatic cancer cell populations possess tumor-initiating capabilities is critical to characterizing and understanding the biology of pancreatic CSCs towards therapeutic ends... - The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapyChristopher Lieu
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Colorectal Cancer 9:89-94. 2010..Further evaluation with biomarkers will continue to define the molecular phenotype of patients with CRC who will benefit the most from Src-based therapy... - Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancerSang Cheul Oh
Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Gut 61:1291-8. 2012.... - Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapyDavid Z Chang
Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
J Hematol Oncol 2:18. 2009..It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies... - Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stressScott Kopetz
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center and Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 4009, USA
Cancer Res 69:3842-9. 2009..These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations... - Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical courseMichael P Herman
Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 74:818-23. 2009..Our goal was to determine the incidence, risk factors, and clinical course of SI fractures in patients treated with preoperative chemoradiation for rectal cancer... - Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancerDavid R Fogelman
M D Anderson Cancer Center, Houston, TX 77030, USA
Anticancer Res 31:1417-20. 2011..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer... - Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisChristopher Lieu
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 17:6130-9. 2011..Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients... - Emerging drugs for colorectal cancerDavid R Fogelman
MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
Expert Opin Emerg Drugs 13:629-42. 2008..Our understanding of existing drugs, such as oxaliplatin and irinotecan, has become more refined. The incorporation of newer drugs such as bevacizumab and cetuximab has expanded treatment options as well... - Use of research biopsies in clinical trials: are risks and benefits adequately discussed?Michael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 31:17-22. 2013..Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use... - Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathwaysLaura S Angelo
Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 10:2094-103. 2011..The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth. Our results provide a rationale for combining curcumin and KNK437 in the treatment of NF2... - Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapyChristopher R Kauffman
Section of Interventional Radiology, Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 112:2283-8. 2008..The purpose of this study was to review our institutional experience with PSE for cancer patients with thrombocytopenia because of splenic sequestration precluding the administration of systemic therapy (ST)... - MicroRNAs, ultraconserved genes and colorectal cancersSimona Rossi
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Biochem Cell Biol 42:1291-7. 2010.... - Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in managementScott Kopetz
Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Oncology (Williston Park) 19:11-7. 2005..Combination regimens and second-line therapy should be offered to elderly patients who have adequate performance status and no contraindicated comorbid conditions, without regard for their chronological age... - Clinical findings of a palliative care consultation team at a comprehensive cancer centerNavneet Dhillon
Department of Palliative Care and Rehabilitation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
J Palliat Med 11:191-7. 2008..As clinical findings of these teams have been reported infrequently, we aim to describe the experience of our high-volume inpatient PCCT... - Novel targets for systemic therapy of colorectal cancerScott Kopetz
GI Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Adv Hematol Oncol 6:38-40. 2008 - PI-3-Kinase inhibitors in colorectal cancerN T Ihle
University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Curr Cancer Drug Targets 11:190-8. 2011..How these goals may be achieved in the current oncology landscape is addressed in this review with an emphasis on how these agents fit the goal of achieving personalized medicine...